VERA ▲ +0.3% - Vera Therapeutics, Inc.
$VERA - Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026
02-OCT-2026 09:24 AM ET
Share this post
More filings for $VERA
VERA ▲ +2.7% - Vera Therapeutics, Inc.Sep 15, 2026VERA ▲ +2.9% - Vera Therapeutics, Inc.Sep 4, 2026VERA ▼ -1.1% - Vera Therapeutics, Inc.Sep 1, 2026VERA - Vera Therapeutics, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026VERA - Vera Therapeutics, Inc. - SEC Filing Update (07-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 7, 2026$VERA SEC Filing Update (30-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 30, 2026
View full $VERA filing history →💬 Comments
Loading comments…
Leave a comment